Combining Segments 9 and 10 in DNA and Recombinant Protein Vaccines Conferred Superior Protection Against Tilapia Lake Virus in Hybrid Red Tilapia ( Sp.) Compared to Single Segment Vaccines

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 12

PMID 35958595

Authors

Pitakthai Chamtim

Eukote Suwan

Ha Thanh Dong

Soranuth Sirisuay

Nontawith Areechon

Eakapol Wangkahart

Ikuo Hirono

Rapeepat Mavichak

Sasimanas Unajak

Affiliations

Soon will be listed here.

Abstract

Tilapia lake virus (TiLV) now affects Nile tilapia culture worldwide, with no available commercial vaccine for disease prevention. DNA and recombinant protein-based vaccines were developed and tested following viral isolation and characterization. The viral strain isolated from diseased hybrid red tilapia ( sp.) shared high levels of morphological and genomic similarity (95.49-99.52%) with other TiLV isolates in the GenBank database. TiLV segment 9 (Tis9) and segment 10 (Tis10) DNA vaccines (pcDNA-Tis9 and pcDNA-Tis10) and recombinant protein vaccines (Tis9 and Tis10) were prepared and tested for their efficacy in juvenile hybrid red tilapia. Fish were immunized with either single vaccines (pcDNA-Tis9, pcDNA-Tis10, Tis9 and Tis10) or combined vaccines (pcDNA-Tis9 + pcDNA-Tis10 and Tis9 + Tis10) by intramuscular injection and intraperitoneal injection for DNA and protein vaccines, respectively. Negative controls were injected with PBS or a naked pcDNA3.1 vector in the same manner. An experimental challenge with TiLV was carried out at 4 weeks post-vaccination (wpv) by intraperitoneal injection with a dose of 1 × 10 TCID per fish. Relative percent survival (RPS) ranged from 16.67 ± 00.00 to 61.11 ± 9.62%. The Tis10 and pcDNA-Tis10 vaccines conferred better protection compared to Tis9 and pcDNA-Tis9. Highest levels of protection were observed in pcDNA-Tis9 + pcDNA-Tis10 (61.11 ± 9.62%) and Tis9 + Tis10 (55.56 ± 9.62%) groups. Specific antibody was detected in all vaccinated groups at 1-4 wpv by Dot Blot method, with the highest integrated density at 2 and 3 wpv. analysis of Tis9 and Tis10 revealed a number of B-cell epitopes in their coil structure, possibly reflecting their immunogenicity. Findings suggested that the combination of Tis9 and Tis10 in DNA and recombinant protein vaccine showed high efficacy for the prevention of TiLV disease in hybrid red tilapia.

Citing Articles

Expression and purification of recombinant tilapia lake virus segment 4 protein and its in-vitro biological activity for potential use in vaccine development.

Sanyalukruechai C, Watthanasakphuban N, Khemthong M, Surachetpong W, Rattanaporn K Sci Rep. 2024; 14(1):31529.

PMID: 39733177 PMC: 11682462. DOI: 10.1038/s41598-024-83293-8.

Computational design of novel chimeric multiepitope vaccine against bacterial and viral disease in tilapia (Oreochromis sp.).

Pumchan A, Proespraiwong P, Sawatdichaikul O, Phurahong T, Hirono I, Unajak S Sci Rep. 2024; 14(1):14048.

PMID: 38890454 PMC: 11189486. DOI: 10.1038/s41598-024-64383-z.

Tilapia lake virus: A structured phylogenetic approach.

Abbadi M, Basso A, Biasini L, Quartesan R, Buratin A, Davidovich N Front Genet. 2023; 14:1069300.

PMID: 37144122 PMC: 10151519. DOI: 10.3389/fgene.2023.1069300.

Tilapia Lake Virus Vaccine Development: A Review on the Recent Advances.

Kembou-Ringert J, Steinhagen D, Readman J, Daly J, Adamek M Vaccines (Basel). 2023; 11(2).

PMID: 36851129 PMC: 9961428. DOI: 10.3390/vaccines11020251.

References

Wang S, Li W, Liu S, Xu J . RaptorX-Property: a web server for protein structure property prediction. Nucleic Acids Res. 2016; 44(W1):W430-5. PMC: 4987890. DOI: 10.1093/nar/gkw306. View

Adams A . Progress, challenges and opportunities in fish vaccine development. Fish Shellfish Immunol. 2019; 90:210-214. DOI: 10.1016/j.fsi.2019.04.066. View

Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y . The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2014; 12(1):7-8. PMC: 4428668. DOI: 10.1038/nmeth.3213. View

Acharya V, Chakraborty H, Rout A, Balabantaray S, Behera B, Das B . Structural Characterization of Open Reading Frame-Encoded Functional Genes from Tilapia Lake Virus (TiLV). Mol Biotechnol. 2019; 61(12):945-957. DOI: 10.1007/s12033-019-00217-y. View

Doytchinova I, Flower D . VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007; 8:4. PMC: 1780059. DOI: 10.1186/1471-2105-8-4. View

Palang I, Hirono I, Senapin S, Sirimanapong W, Withyachumnarnkul B, Vanichviriyakit R . Cytotoxicity of Streptococcus agalactiae secretory protein on tilapia cultured cells. J Fish Dis. 2020; 43(10):1229-1236. DOI: 10.1111/jfd.13230. View

Tattiyapong P, Dachavichitlead W, Surachetpong W . Experimental infection of Tilapia Lake Virus (TiLV) in Nile tilapia (Oreochromis niloticus) and red tilapia (Oreochromis spp.). Vet Microbiol. 2017; 207:170-177. DOI: 10.1016/j.vetmic.2017.06.014. View

Lueangyangyuen A, Senapin S, Dong H, Unajak S, Wangkahart E, Khunrae P . Expression and purification of S5 and S6 proteins from Tilapia Lake Virus (TiLV) and their potential use as vaccines. Protein Expr Purif. 2021; 190:106013. DOI: 10.1016/j.pep.2021.106013. View

Azim K, Lasker T, Akter R, Hia M, Bhuiyan O, Hasan M . Combination of highly antigenic nucleoproteins to inaugurate a cross-reactive next generation vaccine candidate against Arenaviridae family. Heliyon. 2021; 7(5):e07022. PMC: 8144012. DOI: 10.1016/j.heliyon.2021.e07022. View

10.

Wang Y, Wang E, He Y, Wang K, Yang Q, Wang J . Identification and screening of effective protective antigens for channel catfish against Streptococcus iniae. Oncotarget. 2017; 8(19):30793-30804. PMC: 5458168. DOI: 10.18632/oncotarget.16475. View

11.

Ponomarenko J, Bui H, Li W, Fusseder N, Bourne P, Sette A . ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008; 9:514. PMC: 2607291. DOI: 10.1186/1471-2105-9-514. View

12.

Heo L, Park H, Seok C . GalaxyRefine: Protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 2013; 41(Web Server issue):W384-8. PMC: 3692086. DOI: 10.1093/nar/gkt458. View

13.

Mugimba K, Lamkhannat M, Dubey S, Mutoloki S, Munangandu H, Evensen O . Tilapia lake virus downplays innate immune responses during early stage of infection in Nile tilapia (Oreochromis niloticus). Sci Rep. 2020; 10(1):20364. PMC: 7684318. DOI: 10.1038/s41598-020-73781-y. View

14.

Del-Pozo J, Mishra N, Kabuusu R, Cheetham S, Eldar A, Bacharach E . Syncytial Hepatitis of Tilapia ( Oreochromis niloticus L.) is Associated With Orthomyxovirus-Like Virions in Hepatocytes. Vet Pathol. 2016; 54(1):164-170. DOI: 10.1177/0300985816658100. View

15.

Thawornwattana Y, Dong H, Phiwsaiya K, Sangsuriya P, Senapin S, Aiewsakun P . Tilapia lake virus (TiLV): Genomic epidemiology and its early origin. Transbound Emerg Dis. 2020; 68(2):435-444. DOI: 10.1111/tbed.13693. View

16.

Pumchan A, Krobthong S, Roytrakul S, Sawatdichaikul O, Kondo H, Hirono I . Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.). Sci Rep. 2020; 10(1):603. PMC: 6969146. DOI: 10.1038/s41598-019-57283-0. View

17.

Matsuura Y, Terashima S, Takano T, Matsuyama T . Current status of fish vaccines in Japan. Fish Shellfish Immunol. 2019; 95:236-247. DOI: 10.1016/j.fsi.2019.09.031. View

18.

Chaput D, Bass D, Alam M, Hasan N, Stentiford G, van Aerle R . The Segment Matters: Probable Reassortment of Tilapia Lake Virus (TiLV) Complicates Phylogenetic Analysis and Inference of Geographical Origin of New Isolate from Bangladesh. Viruses. 2020; 12(3). PMC: 7150994. DOI: 10.3390/v12030258. View

19.

Ma J, Bruce T, Jones E, Cain K . A Review of Fish Vaccine Development Strategies: Conventional Methods and Modern Biotechnological Approaches. Microorganisms. 2019; 7(11). PMC: 6920890. DOI: 10.3390/microorganisms7110569. View

20.

Mugimba K, Chengula A, Wamala S, Mwega E, Kasanga C, Byarugaba D . Detection of tilapia lake virus (TiLV) infection by PCR in farmed and wild Nile tilapia (Oreochromis niloticus) from Lake Victoria. J Fish Dis. 2018; . DOI: 10.1111/jfd.12790. View